logo
PURE Bioscience Unveils Revolutionary Membrane Treatment Solution for the Dairy and Beverage Industry

PURE Bioscience Unveils Revolutionary Membrane Treatment Solution for the Dairy and Beverage Industry

Yahoo2 days ago

EL CAJON, Calif., June 02, 2025--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, is proud to announce an innovative application method for membrane treatment in the dairy and beverage industry using our flagship product, PURE® Hard Surface. This groundbreaking solution addresses common membrane fouling and sanitization challenges, delivering outstanding results that enable operators to restore throughput and sanitize the membrane without damage or oxidation.
Tom Myers, EVP of Technology & Development at PURE Bioscience, stated, "The introduction of PURE Hard Surface to the Dairy and Beverage industry represents a significant advancement in membrane treatment technology. This product delivers unmatched efficiency and enhances filtration operation and longevity."
Key Attributes of PURE Hard Surface for Membrane Treatment:
One Treatment—Zero Compromises: Achieve superior results with just one treatment. PURE Hard Surface effectively removes fouling, restores flow, and delays the need for membrane replacement without compromising membrane integrity.
Proven Performance: Our solution boasts results with successful treatments demonstrating an impressive 4+ log reduction in 120 seconds. Additionally, it is NSF-listed, making it ideal for eliminating harmful bacteria in the dairy industry without causing membrane oxidation.
Complete Penetration in Minutes: In practical applications, our treatment has shown complete membrane penetration within 5 minutes for reverse osmosis (RO) systems, effectively scrubbing away fouling and restoring throughput. Similarly, our ultrafiltration treatment (UF) systems resulted in immediate penetration and unmatched restoration of throughput while sanitizing to meet stringent quality specifications.
Simplicity and Effectiveness: Membrane operators prefer PURE Hard Surface for its no-hassle approach. The ready-to-use formula requires no mixing—fill and go. Plus, with the lowest EPA toxicity rating, there is no need for personal protective equipment, making it highly safe for staff.
Environmentally Safe: Our treatment poses no risks to wastewater systems, ensuring no impact on digesters or discharge permit compliance.
Cost-Effective Solution: With just one treatment, manufacturers can sell full-priced finished goods, reduce operational costs, and significantly prolong the lifespan of their membranes, contributing to overall operational efficiency.
"Our SDC technology is redefining what's possible in the food industry – and PURE Hard Surface is at the forefront," said Tim Steffensmeier, Vice President of Sales. "This modern membrane application brings a smarter, more efficient approach to streamlining operation, delivering a measurable cost savings, and empowers manufacturers to uphold the highest quality standards in the industry, without the negative trade-offs of traditional chemistry."
Discover the transformative benefits of PURE Hard Surface for membrane treatment. For more information, visit www.purebio.com/membrane, contact one of our key distributors, or come to our booth at the Dairy Foods Membrane Technology Forum, June 2-4, 20025 in Bloomington, MN.
How SDC Works
SDC kills microorganisms by two modes of action: 1) the silver ion deactivates structural and metabolic membrane proteins, leading to microbial death; 2) the microbes view SDC as a food source, allowing the silver ion to enter the microbe. Once inside the organism, the silver ion denatures the DNA, which halts the microbe's ability to replicate and leads to its death. This dual action makes SDC highly and quickly effective against a broad spectrum of microbes. Traditional silver-based disinfectants have short shelf lives – from hours to days. SDC is a stabilized silver ion complex with a shelf life of several years. The unique bond between the silver ions in SDC allows them to remain in solution while making them more bioavailable for antimicrobial action.
About PURE Bioscience, Inc.
PURE focuses on developing and commercializing our proprietary antimicrobial products, primarily in food safety. We provide best-in-class solutions to combat the health and environmental challenges of pathogens and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. PURE's mailing address is 771 Jamacha Rd. #512, El Cajon, California 92019 (San Diego County area), which serves as its official address for all business requirements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602576635/en/
Contacts
Tim Steffensmeier, Vice President of SalesEmail: tsteffensmeier@purebio.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MangoBoost Sets New Benchmark for Multi-Node LLM Training on AMD GPUs in MLPerf Training v5.0
MangoBoost Sets New Benchmark for Multi-Node LLM Training on AMD GPUs in MLPerf Training v5.0

Business Wire

time24 minutes ago

  • Business Wire

MangoBoost Sets New Benchmark for Multi-Node LLM Training on AMD GPUs in MLPerf Training v5.0

BELLEVUE, Wash.--(BUSINESS WIRE)--MangoBoost, a provider of cutting-edge system solutions for maximizing compute efficiency and scalability, has validated the scalability and efficiency of large-scale AI training on AMD Instinct™ MI300X GPUs through its MLPerf Training v5.0 submission. Tailored for enterprise data centers prioritizing performance, flexibility, and cost-efficiency, this milestone demonstrates that state-of-the-art LLM training is now viable beyond traditional vendor-locked GPU platforms. This showcases how the AMD Instinct™ MI300X GPUs and ROCm™ software stack synergize with MangoBoost's LLMBoost™ AI Enterprise software and GPUBoost™ RoCEv2 NIC. Share Using 32 AMD Instinct™ MI300X GPUs across four nodes, MangoBoost fine-tuned the Llama2-70B-LoRA model in just 10.91 minutes, setting the fastest multi-node MLPerf benchmark on AMD GPUs to date. The system achieved near-linear scaling efficiency (95–100%), proving that MangoBoost's stack can support practical and scalable LLM training in production environments. Scalability and Efficiency for Enterprise Data Centers The result showcases more than just benchmark success—it underscores how enterprises can reliably scale LLM training across clusters without network bottlenecks or rigid infrastructure dependencies. Mango LLMBoost™: A full-featured MLOps software platform for large language models, supporting model parallelism, automatic tuning, batch scheduling, and advanced memory management. Mango GPUBoost™ RoCEv2 RDMA: Inter-GPU communication hardware optimized for low-latency, high-throughput node-to-node communication, sustaining line-rate performance across thousands of concurrent QPs. These technologies together deliver predictable and efficient multi-node training, ideal for organizations operating their own AI infrastructure or deploying on public cloud. Industry-First MLPerf Training on AMD MI300X GPUs This is the first-ever MLPerf Training submission on AMD GPUs spanning multiple nodes. MangoBoost's platform demonstrated robust performance with a 4-node, 32-GPU cluster and confirmed compatibility with additional model sizes and structures—including Llama2-7B and Llama3.1-8B—in internal benchmarks. These results validate the generalizability of MangoBoost's platform beyond benchmarks to diverse production-scale use cases. " I'm excited to see MangoBoost's first MLPerf Training results, pairing their LLMBoost AI Enterprise MLOps software with their RoCEv2-based GPUBoost DPU hardware to unlock the full power of AMD GPUs, demonstrated by their scalable performance from a single-node MI300X to 2- and 4-node MI300X results on Llama2-70B LoRA. Their results underscore that a well-optimized software stack is critical to fully harness the capabilities of modern AI accelerators." — David Kanter, Founder, Head of MLPerf, MLCommons Vendor-Neutral AI Infrastructure Enabled by AMD Collaboration The achievement was made possible through deep collaboration with AMD and seamless integration with the ROCm™ software ecosystem, enabling full utilization of MI300X's compute, memory bandwidth, and capacity. Enterprises are now empowered to choose infrastructure based on business needs—not vendor constraints. " We congratulate MangoBoost on their MLPerf 5.0 training results on AMD GPUs and are excited to continue our collaboration with them to unleash the full power of AMD GPUs. In this MLPerf Training submission, MangoBoost has achieved a key milestone in demonstrating training results on AMD GPUs across 4 nodes (32 GPUs). This showcases how the AMD Instinct™ MI300X GPUs and ROCm™ software stack synergize with MangoBoost's LLMBoost™ AI Enterprise software and GPUBoost™ RoCEv2 NIC." — Meena Arunachalam, Fellow, AI Performance Design Engineering, AMD "At MangoBoost, we've shown that software-hardware co-optimization enables scalable, efficient LLM training without vendor lock-in. Our MLPerf result is a key milestone proving our technology is ready for enterprise-scale AI training with superior efficiency and flexibility," said CEO Jangwoo Kim. MangoBoost continues to develop innovations in communication optimization, hybrid parallelism, topology-aware scheduling, and domain-specific acceleration to further scale performance in distributed AI workloads. About MangoBoost MangoBoost is a provider of cutting-edge, full-stack system solutions for maximizing compute efficiency and scalability. At the heart of the solutions is the MangoBoost Data Processing Unit (DPU), which ensures full compatibility with general-purpose GPUs, accelerators, and storage devices, enabling cost-efficient, standardized AI infrastructure. Founded in 2022 on a decade of research, MangoBoost is rapidly expanding its operations in the U.S., Canada, and Korea.

Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook
Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook

Yahoo

time25 minutes ago

  • Yahoo

Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook

Thor Industries, Inc. (NYSE:THO) shares are trading higher on Wednesday after the company reported third-quarter EPS of $2.53 beating the street consensus of $1.83. Quarterly sales of $2.89 billion, up 3.3% year over year (Y/Y), outpaced the analyst consensus estimate of $2.48 billion. Gross profit margin in the quarter under review expanded by 20 basis points year over year to 15.3%.Adjusted EBITDA increased 7.9% Y/Y to $254.8 million in the quarter. North American Towable Recreational Vehicle (RV) net sales increased 9.1% Y/Y, while North American Motorized RV net sales rose 3.1% Y/Y in the quarter. North American Towable RV net sales benefitted from 5.5% higher unit shipments and a 3.6% increase in net price per unit. Gross profit margin improved 200 basis points to 14.9%, attributed to higher sales, less discounting, better warranty costs, and ongoing savings. North American Motorized RV net sales increased due to a 10.9% rise in unit shipments (partly from promotions), though a 7.8% decrease in net price per unit (due to product mix shift and higher discounting) partially offset this. Gross profit margin fell to 10.5% from 11.1%, primarily owing to increased sales discounting. As of April 30, the order backlog for North American Towable RV stood at $634.3 million (-14.4%) and North American Motorized RV came in at $883.7 million (-4.5%). European RV net sales decreased 5.1% Y/Y for the quarter, led by a 12.2% decrease in unit shipments, which was offset in part by a 7.1% Y/Y increase in the overall net price per unit. European RV net sales fell due to a 12.2% drop in unit shipments, partially offset by a 7.1% increase in net price per unit. The price increase included a 6.8% rise from product mix and pricing changes, plus a 0.3% benefit from foreign currency exchange rates. European RV gross profit margin contracted 130 basis points to 16.2% on increased sales discounting. As of April 30, the order backlog for European RV came in at $1.34 billion (-30.6%). The company exited the quarter with cash and cash equivalents worth $508.3 million, with net inventories worth $1.35 billion. Long-term debt (net) at the end of the quarter stood at $1.01 billion. Todd Woelfer, senior VP and COO, said, 'As we anticipated and messaged at the beginning of our fiscal year, our North American Motorized and European segments have both seen year-over-year declines in gross margin but still achieved resilient results considering the challenging environments facing those segments.' 'While our consolidated margin this quarter was unfavorably impacted by actions we took to deepen our partnerships with key dealers, strategically, deepening these key relationships is vital to our long-term market position and these decisions favorably position THOR for the future as we look ahead,' Thor Industries reaffirmed its FY25 EPS guidance of $3.30 to $4.00 compared to analyst estimates of $3.59. The company also maintained its FY25 sales guidance at $9.00 billion to $9.50 billion versus the analyst estimate of $9.25 billion. Bob Martin, president and CEO, added, 'Our financial guidance assumed a stronger second half of our fiscal year, and our fiscal third quarter performance reflects the value of our strategies in the currently difficult market.' 'We expect the fourth quarter of our fiscal 2025 and the first quarter of our fiscal 2026 to be challenging. The current economic uncertainty has led to downward pressure on consumer confidence and has negatively impacted retail pull-through. We believe that upon the resolution of this uncertainty, we will see improved consumer confidence and the return of a strong retail environment,' he added. Year-to-date, the stock has declined around 11%. The short float for Thor Industries is 18.33%, according to data from Benzinga Pro. Price Action: THO shares are trading higher by 3.44% to $85.25 at last check Wednesday. Read Next:Image by Michael Gordon via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? THOR INDUSTRIES (THO): Free Stock Analysis Report This article Recreational Vehicle Maker Thor's European Sales Hit By Dip, Cautions On Macro Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

QPS Celebrates 30th Anniversary
QPS Celebrates 30th Anniversary

Yahoo

time29 minutes ago

  • Yahoo

QPS Celebrates 30th Anniversary

NEWARK, Del., June 04, 2025--(BUSINESS WIRE)--QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a global CRO with more than 1,200 employees. "30 years is a major milestone for QPS and I couldn't be more proud of the hard-working and innovative people who choose to work at QPS. They are the backbone of the company, and I am very grateful for their valuable contributions," said founder and CEO of QPS, Dr. Benjamin Chien. "Through QPS, the pharmaceutical and biotechnology industries have access to dedicated, focused scientific expertise across the drug development spectrum. In facilities around the world, QPS has assembled best-in-class instruments, platforms, people and processes required to conduct the studies necessary to support client drug discovery and development programs focused on obesity, type 2 diabetes, oncology, CNS diseases, cell and gene therapy, and more," said Dr. Chien. Since its humble beginnings, QPS has expanded its service options, to include pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, central lab services, and a full range of clinical research services. QPS is known for high-quality data, technical expertise, delivery of promised study timelines, collaborative solutions, and customer-focused strategies. Going forward, QPS plans to continue delivering custom-built research services that accelerate pharmaceutical breakthroughs across the globe. ABOUT QPS HOLDINGS, LLC QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit or email info@ View source version on Contacts QPS CONTACT: Name: Gabrielle PastorePhone: 1-302-635-4290Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store